Alert: This Sector Is Melting UPSteve Sjuggerud here. Even after decades in the markets, I still get nervous to see headlines like this pop up... The thing is – it's not because I'm actually worried stocks will "crash." Instead, I'm worried you'll miss the opportunity... Get sucked in by a media narrative telling you to run. When in reality, you should be doing the exact opposite. This "dip" is an opportunity. A big one. Especially in one of the hottest sectors in the world right now (which typically SOARS in a Melt Up environment like this) – biotechnology. This is NOT a time to panic. It's a great chance to get in on massive-upside biotech stocks ahead of what could be another very sharp leg higher. ***Despite the headlines, this market is still an incredible opportunity for investors today... Now, the absolute best person to follow into this space is my colleague Dave Lashmet. Dave's recently shown readers quadruple digit gains in just four months after the March crash... And he's sitting on average gains of 193% for his closed positions in 2020. In short: He's lived and breathed biotech for decades... and holds one of the most consistent portfolios of any analyst, bar none. HALF of all of Dave's closed positions so far (ALL-TIME) in his top biotech service have almost doubled... or have soared into triple-digit wins and above. But what's more exciting is that Dave just went "all in" on what he's calling his "pick of the decade" – a small-cap drug company sitting on a potential cure for obesity. According to Dave: The potential is hiding in the fine print. An "orphan" drug... fast-tracked for approval... could soon be prescribed to 70% of all Americans... and that's not an exaggeration. It's a rare chance to see 20-bagger potential if you get in before this hits mainstream headlines. He's detailed all the critical details right here. Given Dave's track-record... coupled with the enormous upside in biotech today... this is simply too good to miss.. So, get your pen and pad ready to take notes... then click here for details. Good investing, Steve Sjuggerud P.S. The Melt Up in biotech is minting new fortunes left and right... Just look at Gustavo Denegri. His 45% stake on biotech company (DiaSorin) increased his net worth by 32%, or $1.1 billion.And Maja Oeri increased her $3.2 billion net worth by 10% thanks to a huge drug company (Roche).But the gains in smaller-cap ideas like Dave's latest recommendation could be far bigger. But time is of the essence... Get all the details this weekend, right here. | 